FCMI
Foresite Capital Management III Portfolio holdings
AUM
$37.9M
This Quarter Return
-7.35%
1 Year Return
-6.87%
3 Year Return
+443.49%
5 Year Return
+535.97%
10 Year Return
–
AUM
$39.5M
AUM Growth
+$39.5M
(-45%)
Cap. Flow
-$33.5M
Cap. Flow
% of AUM
-84.93%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
2
Increased
–
Reduced
–
Closed
4
Top Buys
| 1 |
Ascendis Pharma
ASND
|
$18M |
| 2 |
Natera
NTRA
|
$8.5M |
Top Sells
| 1 |
Aclaris Therapeutics
ACRS
|
$35.2M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$18.7M |
| 3 |
EPZM
Epizyme, Inc
EPZM
|
$5.11M |
| 4 |
Novavax
NVAX
|
$1.04M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Ascendis Pharma
ASND
$11.8B
| $18M | 45.53% | +133,691 | New | +$18M |
|
|
2
Natera
NTRA
$23.1B
| $8.5M | 21.51% | +91,000 | New | +$8.5M |
|
|
VRNA
3
Verona Pharma
VRNA
$9.16B
| $7.47M | 18.9% | 1,111,112 | – | – |
|
|
CBAY
4
DELISTED
Cymabay Therapeutics
CBAY
| $5.55M | 14.05% | 1,641,804 | – | – |
|
|
5
Aclaris Therapeutics
ACRS
$209M
| – | – | -1,954,904 | Closed | -$35.2M |
|
|
6
Novavax
NVAX
$1.21B
| – | – | -5,000 | Closed | -$1.04M |
|
|
EPZM
7
DELISTED
Epizyme, Inc
EPZM
| – | – | -998,278 | Closed | -$5.11M |
|
|
XLRN
8
DELISTED
Acceleron Pharma Inc.
XLRN
| – | – | -108,630 | Closed | -$18.7M |
|